Literature DB >> 16601593

Treatment of a congenital pseudarthrosis of the tibia by osteogenic protein-1 (bone morphogenetic protein-7): a case report.

Darko Anticevic1, Mislav Jelic, Slobodan Vukicevic.   

Abstract

Congenital pseudarthrosis of the tibia remains one of the most difficult orthopaedic problems to treat. Before the use of a recombinant bone morphogenetic protein (bone morphogenetic protein-7; osteogenic protein-1) the patient with congenital pseudarthrosis of the tibia in this report had had 12 unsuccessful surgeries. Five months after radical resection of sclerotic tibial segments, Ilizarov fixation and administration of osteogenic protein-1 osteogenic device, the congenital pseudarthrosis of the tibia healed; at 45 months the tibia increased in size and the patient was fully weight bearing.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16601593     DOI: 10.1097/01.bpb.0000194439.75378.ac

Source DB:  PubMed          Journal:  J Pediatr Orthop B        ISSN: 1060-152X            Impact factor:   1.041


  14 in total

1.  Bone morphogenetic protein-2 for the treatment of congenital pseudarthrosis of the tibia or persistent tibial nonunion in children and adolescents: A retrospective study with a minimum 2-year follow-up.

Authors:  Tim N Hissnauer; Norbert Stiel; Kornelia Babin; Martin Rupprecht; Michael Hoffmann; Johannes M Rueger; Ralf Stuecker; Alexander S Spiro
Journal:  J Mater Sci Mater Med       Date:  2017-02-17       Impact factor: 3.896

Review 2.  [Malformations of the lower extremities].

Authors:  F Hefti
Journal:  Orthopade       Date:  2008-04       Impact factor: 1.087

3.  Bone morphogenetic protein and orthopaedic surgery: can we legitimate its off-label use?

Authors:  Aurélien Courvoisier; Frederic Sailhan; Olivier Laffenêtre; Laurent Obert
Journal:  Int Orthop       Date:  2014-09-30       Impact factor: 3.075

4.  Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.

Authors:  Jean de la Croix Ndong; David M Stevens; Guillaume Vignaux; Sasidhar Uppuganti; Daniel S Perrien; Xiangli Yang; Jeffry S Nyman; Eva Harth; Florent Elefteriou
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741

Review 5.  The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing.

Authors:  Slobodan Vukicevic; Hermann Oppermann; Donatella Verbanac; Morana Jankolija; Irena Popek; Jasna Curak; Jelena Brkljacic; Martina Pauk; Igor Erjavec; Igor Francetic; Ivo Dumic-Cule; Mislav Jelic; Dragan Durdevic; Tomislav Vlahovic; Ruder Novak; Vera Kufner; Tatjana Bordukalo Niksic; Marija Kozlovic; Zrinka Banic Tomisic; Jadranka Bubic-Spoljar; Ivancica Bastalic; Smiljka Vikic-Topic; Mihaela Peric; Marko Pecina; Lovorka Grgurevic
Journal:  Int Orthop       Date:  2013-12-19       Impact factor: 3.075

6.  The reduced osteogenic potential of Nf1-deficient osteoprogenitors is EGFR-independent.

Authors:  S E Tahaei; G Couasnay; Y Ma; N Paria; J Gu; B F Lemoine; X Wang; J J Rios; F Elefteriou
Journal:  Bone       Date:  2017-10-12       Impact factor: 4.398

7.  Masquelet's procedure and bone morphogenetic protein in congenital pseudarthrosis of the tibia in children: a case series and meta-analysis.

Authors:  Bruno Dohin; Remi Kohler
Journal:  J Child Orthop       Date:  2012-07-21       Impact factor: 1.548

8.  [Percutaneous administration of recombinant human bone morphogenetic protein-7 (rhBMP-7) after callus distraction. Two case reports].

Authors:  F Högel; M Militz; V Bühren; P Augat; F Wagner
Journal:  Unfallchirurg       Date:  2011-02       Impact factor: 1.000

9.  Congenital pseudarthrosis of the tibia: the results of an evolving protocol of management.

Authors:  N Nicolaou; A Ghassemi; R A Hill
Journal:  J Child Orthop       Date:  2013-06-12       Impact factor: 1.548

10.  Enhancement of difficult nonunion in children with osteogenic protein-1 (OP-1): early experience.

Authors:  Bruno Dohin; Noémi Dahan-Oliel; François Fassier; Reggie Hamdy
Journal:  Clin Orthop Relat Res       Date:  2009-07-09       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.